Gilead Oncology Grant Supports 22 U.S. Organizations With $3.15 Million to Provide Support to Those Affected By Breast Cancer
Rhea-AI Summary
Gilead Sciences has announced a $3.15 million grant initiative supporting 22 U.S. organizations focused on providing resources and assistance to individuals affected by breast cancer. The initiative, known as the Gilead Oncology Grant, aims to promote health equity across the cancer care continuum. This funding demonstrates Gilead's commitment to transforming and simplifying care for patients with life-threatening illnesses.
Positive
- Allocated $3.15 million in grants to support breast cancer initiatives
- Expanded healthcare support network through partnerships with 22 organizations
Negative
- None.
News Market Reaction – GILD
In the trading session that priced this news, GILD gained 0.60%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NORTHAMPTON, MA / ACCESSWIRE / October 31, 2024 / Gilead Sciences
We're prioritizing health equity for patients across the cancer care continuum. Our Gilead Oncology Grant supports 22 U.S. organizations with
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
Originally published by Gilead Sciences
View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.
Contact Info:
Spokesperson: Gilead Sciences
Website: https://www.3blmedia.com/profiles/gilead-sciences
Email: info@3blmedia.com
SOURCE: Gilead Sciences
View the original press release on accesswire.com